Apyx Medical Corporation Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Apyx Medical Corp. (APYX) Tops Q2 EPS by 7c, Revenues Beat
August 10, 2020 7:17 AM EDTApyx Medical Corp. (NASDAQ: APYX) reported Q2 EPS of ($0.14), $0.07 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $1.96 million.
Second Quarter 2020 Financial Summary:
Total revenue of $4.3 million, down 35% year-over-year.Advanced Energy revenue of $2.9 million, down 46% year-over-year.OEM revenue of $1.4 million, up 10% year-over-year.GAAP net loss of $4.7 million, compared to total GAAP net loss of $4.3 million for the second quarter of 2019.Adjusted EBITDA loss of $4.9 million, compared to adjusted EBITDA loss of $3.6 million for the second... More